In this case the taxpayer, a doctorsâ office, displayed various pieces of art in its offices, claimed depreciation on said artwork, which the IRS disallowed. At trial the IRS argued that the works of art did not have a useful life, based on Revenue Ruling 68-232.
A reduction in HAPU incidence by just 1 percentage point (3.5% to 2.5%) results in potential savings of $1,305,000 per year. Calculate your own potential savings below.
The researchers estimated that 1.6 million people will be eligible for hep C treatment during the next five years. Paying for all their treatment would cost insurers $136 billion, a figure that is $65 billion higher than treating with the older drug regimens. Treating with the new, more effective Harvoni would save $16 billion in drug costs. The study assumed that Harvoni costs insurers $1,125 per day, the set price for the single-tablet therapy. However, in recent months various pharmacy benefit managers have secured discounts for Harvoni, which may improve the outlook both in terms of cost-effectiveness and overall cost burden.